Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06915324 · ClinicalTrials.gov registry record · NA
Transcranial Direct Current Stimulation for Post Treatment Lyme Disease
A NA study of Post-Treatment Lyme Disease, sponsored by Columbia University.
- Recruiting
- Registry status
- NA
- Development phase
- 110
- Enrollment target
- 2
- Study locations
NCT06915324: Recruiting NA study of Post-Treatment Lyme Disease, sponsored by Columbia University.
NCT06915324 is a NA study of Post-Treatment Lyme Disease that is actively recruiting participants, run by Columbia University. The registered enrollment target is 110 participants, above the 32-participant average among 4 other Post-Treatment Lyme Disease trials with a reported enrollment target (244% higher). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06915324, a NA study of Post-Treatment Lyme Disease, is actively recruiting participants, sponsored by Columbia University.
- RECRUITING
- Registry status
- NA
- Development phase
- 110 participants
- Enrollment target
- 2
- Study locations
Study Summary
The primary purpose of this pilot study is to investigate a novel approach to the treatment of cognitive symptoms that persist despite prior antibiotic treatment for Lyme disease (Post treatment Lyme Disease or PTLD). Aim 1: The primary aim of this study is to assess whether the processing speed of individuals with PTLD can be enhanced by combining transcranial direct current stimulation (tDCS) with computer based cognitive training games. To achieve this aim, over a 4-week period, all individuals with PTLD will participate in at home adaptive cognitive training combined with either active stimulation or sham stimulation. Aim 2: To determine if treatment benefit in processing speed is sustained, the study will compare the sham and active groups 8 weeks after completion of study treatment.
Primary Outcome
The WAIS-IV Coding test is part of the Processing Speed Subtest and consists of three measured abilities, including visual-motor coordination, motor and mental speed, and visual working memory. In this coding task, participants using the key provided at the top of the exercise form draw the symbol under the corresponding number. Subtests yielding scaled scores that sum to derive the full-scale score. The score is the number of correct symbols from 0-133 drawn within a period of 120 seconds. The
Conditions Studied
Interventions
- DEVICE Transcranial Direct Current Stimulation (tDCS)
- BEHAVIORAL Cognitive training
Study Locations (2)
California
- University of California, San Francisco - San Francisco
New York
- Columbia University Department of Psychiatry - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2025-07-14 |
| Est. Completion | 2027-08 |
| Phase | NA |
What NCT06915324 shows while recruiting
NCT06915324 is an interventional study that assigns participants to a tested intervention. The registered 110 participants enrollment target is mid-sized for trials with a published cap, above the 32-participant average among 4 other Post-Treatment Lyme Disease trials with a reported enrollment target (244% higher).
The record links to 1 condition, with Post-Treatment Lyme Disease appearing as the primary indexed condition, and to 2 interventions - of which Transcranial Direct Current Stimulation (tDCS) is the first listed.
NCT06915324 reports a single indexed study location in California, New York.
Frequently Asked Questions
What is clinical trial NCT06915324 about?
NCT06915324 is a clinical study titled "Transcranial Direct Current Stimulation for Post Treatment Lyme Disease". The primary purpose of this pilot study is to investigate a novel approach to the treatment of cognitive symptoms that persist despite prior antibiotic treatment for Lyme disease (Post treatment Lyme Disease or PTLD). Aim 1: The primary aim of this study is to assess whether the processing speed of...
What is the current status of trial NCT06915324?
This trial is currently recruiting. It is a NA study. The enrollment target is 110 participants. The study started on 2025-07-14. Estimated completion is 2027-08.
What conditions does trial NCT06915324 study?
This clinical trial studies the following conditions: Post-Treatment Lyme Disease.
What interventions are being tested in trial NCT06915324?
The interventions under investigation include: Transcranial Direct Current Stimulation (tDCS) (DEVICE), Cognitive training (BEHAVIORAL).
Who is sponsoring clinical trial NCT06915324?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06915324 being conducted?
This trial has 2 study locations across California, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Post-Treatment Lyme Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
taVNS for Persistent Symptoms From Lyme Disease
RECRUITING · NA
-
Pregnancy and Early Neurodevelopmental Outcomes Following In Utero Lyme Disease Exposure
RECRUITING
-
Ceftriaxone Pulse Dose for Post-Treatment Lyme Disease
RECRUITING · Early Phase 1
-
Navigating Pregnancy and Parenthood With Lyme Disease
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01530373 · 110 participants · Phase 2
Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients
- NCT02379377 · 110 participants · Phase 1
18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant
- NCT02411773 · 110 participants · Phase 1
Sympatholysis in Chronic Kidney Disease
- NCT03190941 · 110 participants · Phase 1
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI